Compound 2b induced apoptosis-dependent anticancer activity up to 43.08% (superior to 5-FU), activated p53 by up to 47%, downregulated Bcl2 gene by 1.25 fold, and upregulated p21 by two folds in the treated cancer cells. This evidence concerns the gene TP53 and cancer.